Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients

Introduction: Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data indicate that OAB patients with concomitant diabetes or hypertension, known risk factors of atherosclerosis, may exhibit greater baseline OAB symptoms and slightly smaller therapeutic responses to treatment, but the impact of a combined presence of diabetes and hypertension has not been reported. Therefore, we have explored whether the combined presence of both comorbidities is associated with greater baseline OAB symptoms than that of either comorbidity alone. Secondary questions were exploration of the impact of either comorbidity on baseline symptoms, and of the impact of either comorbidity alone and their combination on therapeutic responses. Methods: Data from two non-interventional studies applying treatment with propiverine ER 30 or 45 mg/d for 12 weeks were analyzed. Results: Number of urgency episodes in the combination group was greater than with each comorbidity alone. The impact of comorbidities on baseline intensity of incontinence, frequency or nocturia or Patient Perception of Bladder Condition was less consistent or absent. Either comorbidity alone was associated with a smaller % improvement of symptoms, and their combination had a greater effect than either alone. However, all attenuations associated with comorbidity were small relative to the overall improvement. Conclusions: We conclude that comorbidities of diabetes and hypertension have detectable effects on OAB symptoms and treatment responses, but the small magnitude of these alterations does not justify changing existing paradigms for the clinical management of OAB.

[1]  J. J. de la Rosette,et al.  Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses , 2022, Frontiers in Pharmacology.

[2]  M. Kas,et al.  The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments , 2022, Nature Methods.

[3]  A. Grechko,et al.  Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment , 2022, Frontiers in Cardiovascular Medicine.

[4]  A. Kannt,et al.  Analysis of 16 studies in nine rodent models does not support the hypothesis that diabetic polyuria is a main reason of urinary bladder enlargement , 2022, Frontiers in Physiology.

[5]  P. Fornara,et al.  Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment , 2022, Neurourology and urodynamics.

[6]  Guiming Liu,et al.  Established and emerging treatments for diabetes-associated lower urinary tract dysfunction , 2022, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  J. J. de la Rosette,et al.  What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine , 2022, Advances in Therapy.

[8]  P. Thürmann,et al.  Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany , 2021, European Journal of Clinical Pharmacology.

[9]  M. Oelke,et al.  Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting , 2021, Journal of clinical medicine.

[10]  J. J. de la Rosette,et al.  Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study , 2020, Frontiers in Pharmacology.

[11]  U. Dirnagl,et al.  Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals , 2020, BMJ Open Science.

[12]  A. Stang,et al.  Do overactive bladder symptoms and their treatment‐associated changes exhibit a normal distribution? Implications for analysis and reporting , 2020, Neurourology and urodynamics.

[13]  Martin C Michel,et al.  New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology , 2019, Drug Metabolism and Disposition.

[14]  H. Motulsky,et al.  New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology , 2019, Molecular Pharmacology.

[15]  S. Greenland,et al.  Scientists rise up against statistical significance , 2019, Nature.

[16]  M. Michel,et al.  A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences , 2018, Neurourology and urodynamics.

[17]  M. Michel,et al.  A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin‐induced rat models , 2018, Neurourology and urodynamics.

[18]  Bing Yang*,et al.  The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study , 2016, Urologia Internationalis.

[19]  K. Azadzoi,et al.  LUTS in pelvic ischemia: a new concept in voiding dysfunction. , 2016, American journal of physiology. Renal physiology.

[20]  J. Lang,et al.  A Population-based Survey of the Prevalence, Potential Risk Factors, and Symptom-specific Bother of Lower Urinary Tract Symptoms in Adult Chinese Women. , 2015, European urology.

[21]  R. Chess-Williams,et al.  Are blood vessels a target to treat lower urinary tract dysfunction? , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  L. Cardozo,et al.  Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies , 2015, International journal of clinical practice.

[23]  E. Barrett-Connor,et al.  Lifestyle and Health Factors Associated with Progressing and Remitting Trajectories of Untreated Lower Urinary Tract Symptoms among Elderly Men , 2014, Prostate Cancer and Prostatic Disease.

[24]  M. Michel,et al.  Does concomitant diabetes affect treatment responses in overactive bladder patients? , 2013, International journal of clinical practice.

[25]  T. Golabek,et al.  Detrusor overactivity in diabetic and non-diabetic patients: is there a difference? , 2012, International braz j urol : official journal of the Brazilian Society of Urology.

[26]  R. Freeman,et al.  Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes , 2011, Diabetes/metabolism research and reviews.

[27]  G. De Nucci,et al.  Characterization of the urinary bladder dysfunction in renovascular hypertensive rats , 2011, Neurourology and urodynamics.

[28]  Matthew T. Haren,et al.  Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men , 2011, World Journal of Urology.

[29]  T. Schneider,et al.  Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? , 2010, International journal of clinical practice.

[30]  C. Porto,et al.  Long‐term nitric oxide deficiency causes muscarinic supersensitivity and reduces β3‐adrenoceptor‐mediated relaxation, causing rat detrusor overactivity , 2008, British journal of pharmacology.

[31]  C. Roehrborn,et al.  Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. , 2006, Urology.

[32]  S. Madersbacher,et al.  The association between vascular risk factors and lower urinary tract symptoms in both sexes. , 2006, European urology.

[33]  E. Giovannucci,et al.  Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III) , 2005, International Journal of Obesity.

[34]  U. Heemann,et al.  Association of hypertension with symptoms of benign prostatic hyperplasia. , 2004, The Journal of urology.

[35]  Michael A. Joseph,et al.  Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. , 2003, American journal of epidemiology.

[36]  M. Michel,et al.  Does gender or age affect the efficacy and safety of tolterodine? , 2002, The Journal of urology.

[37]  M. Barry,et al.  Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. , 2001, Journal of clinical epidemiology.

[38]  P. Abrams,et al.  How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.

[39]  H. Schumacher,et al.  Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. , 2000, The Journal of urology.

[40]  W. Steers,et al.  Altered NGF regulation may link a genetic predisposition for hypertension with hyperactive voiding. , 1999, The Journal of urology.

[41]  W. Steers,et al.  The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males , 1999, Experimental physiology.

[42]  W. Steers,et al.  Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. , 1998, The American journal of physiology.

[43]  H. Schumacher,et al.  Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? , 1998, The Journal of urology.

[44]  W. Steers,et al.  Neurally mediated hyperactive voiding in spontaneously hypertensive rats , 1998, Brain Research.

[45]  U. Wetterauer,et al.  Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine Clinical Use , 2008, Drug safety.

[46]  U. Heemann,et al.  Safety of Telmisartan in Patients with Arterial Hypertension , 2004, Drug safety.

[47]  Carolyn Margraf,et al.  Overactive bladder. , 2002, The American journal of nursing.